CLINICAL_TRIALS
trial_result
· 2025-02-03
Clinical Trial Update: Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Summary
Pfizer's post-marketing commitment study evaluating real-world use of Vyndaqel (tafamidis) in patients with transthyretin familial amyloid polyneuropathy has co…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Transthyretin Familial Amyloid Polyneuropathy | Status: COMPLETED | Results posted: 2025-02-03